Metastatic Biliary Tract Cancer – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Metastatic Biliary Tract Cancer – Drugs In Development, 2024 report and make more profitable business decisions.
Metastatic biliary tract cancer, originating from bile duct cells, spreads to distant areas like the liver, lymph nodes, or lungs. Symptoms, like jaundice and abdominal pain, manifest late. Diagnosis entails imaging scans and biopsies. Treatment focuses on palliative care to alleviate symptoms and prolong life, employing chemotherapy, targeted therapies, or immunotherapy. Prognosis remains guarded due to advanced stage upon diagnosis and limited therapeutic options, often leading to a shorter life expectancy. Clinical trials explore innovative treatments, but metastatic biliary tract cancer poses a significant challenge, emphasizing the importance of symptom management and supportive care to enhance patients’ quality of life.
The Metastatic Biliary Tract Cancer drugs in development market research report provide comprehensive information on the therapeutics under development for Metastatic Biliary Tract Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Biliary Tract Cancer and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Metastatic Biliary Tract Cancer | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 75 molecules, with 74 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Metastatic Biliary Tract Cancer therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Metastatic Biliary Tract Cancer pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Metastatic Biliary Tract Cancer treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Akeso IncAlphamab Oncology
Amgen Inc
AstraZeneca Plc
Avacta Life Sciences Ltd
Bayer AG
BeiGene Ltd
Bio-Thera Solutions Ltd
Biocad
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Cantargia AB
Celltrion Inc
Chang Gung Memorial Foundation
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Chugai Pharmaceutical Co Ltd
Compass Therapeutics Inc
Convalife
Cornerstone Pharmaceuticals Inc
CSPC Pharmaceutical Group Ltd
Cyclacel Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Dragonboat Biopharmaceutical (Shanghai) Co Ltd
Eisai Co Ltd
Eli Lilly and Co
Elpiscience Biopharma Ltd
F. Hoffmann-La Roche Ltd
Glycotope GmbH
GSK plc
Huabo Biopharm (Shanghai) Co Ltd
Hutchison MediPharma Ltd
ImmuneOncia Therapeutics Inc
Innovent Biologics Inc
J-Pharma Co Ltd
Jazz Pharmaceuticals Plc
Jiangsu Hengrui Medicine Co Ltd
Komipharm International Co Ltd
Leap Therapeutics Inc
Les Laboratoires Servier SAS
Lokon Pharma AB
Merck & Co Inc
Merck KGaA
Molecular Templates Inc
Novartis AG
Ohara Pharmaceutical Co Ltd
Ono Pharmaceutical Co Ltd
Pfizer Inc
Puma Biotechnology Inc
Redx Pharma Plc
RemeGen Co Ltd
SciClone Pharmaceuticals Holdings Ltd
Seagen Inc
Shanghai Miracogen Inc
Shanghai Yidian Pharmaceutical Technology Development Co Ltd
Takeda Pharmaceutical Co Ltd
TerSera Therapeutics LLC
Transcenta Holding Ltd
TransThera Sciences (Nanjing) Inc
Wuhan Binhui Biopharmaceutical Co Ltd
ZielBio Inc
Zr Pharma & Gmbh
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Metastatic Biliary Tract Cancer reports